STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G

BCTX Schedule 13G filing by Citadel Advisors

Citadel Advisors reported beneficial ownership of 717.2K shares, representing 9.99% of BriaCell Therapeutics Corp. in this filing.

FiledJan 23, 2026
Ownership dateJan 15, 2026
Reported shares717.2K
Reported ownership9.99%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 0
Shared voting power 717.2K
Sole dispositive power 0
Shared dispositive power 717.2K
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$4.35as of Jan 23, 2026
Latest tracked price$3.54as of Aug 7, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
Citadel Advisors
CIK
CIK0001423053
Accession
0001104659-26-006332
Form
Schedule 13G
Open SEC filing View BCTX ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →